News | December 17, 2023
Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
With the establishment of five different precious metals alloy powder production methods
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Alignment of carbon-fiber can be controlled during the 3D printing process
Subscribe To Our Newsletter & Stay Updated
